Related Experiment Video
Updated: Mar 6, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Accelerating care, capacity and equity in automated insulin delivery systems for New Zealanders with type 1 diabetes:
Jennifer T Gale1,2, Alisa Boucsein1, Jonathan Williman3
1Department of Paediatrics and Child Health, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.
Purpose:
Automated insulin delivery (AID) systems are the gold standard for managing type 1 diabetes (T1D), yet access remains inequitable due to funding disparities, workforce limitations, bias, and geographic barriers. The ACCESS-AID study aims to implement a new model of care by using a remote 'Hub' to deliver prioritised training and support to those most in need and to improve workforce capacity by working in partnership with New Zealand's National Public Health service.
Methods:
Eligible participants include all individuals with T1D and eligible people with pancreatogenic/Type 3c diabetes). Enrolment will use a prioritisation score. After informed consent and baseline assessments, participants receive one-day AID training (in-person or remote) by certified, industry provided trainers, followed by 12-weeks of structured support from Hub staff. The primary outcome is implementation effectiveness. Secondary outcomes: clinical and psychosocial impacts, safety, nutrition education effectiveness, and qualitative insights. CGM metrics and HbA1c will be assessed at baseline and 12-weeks, and CGM again at 24-weeks. Hub staff will receive training in AID management, complete self-efficacy assessments, and participate in interviews.
Conclusion:
This model offers a novel, scalable and equity-focused approach to diabetes technology care, which will enhance outcomes for people with diabetes and inform future service delivery for other long-term conditions.
More Related Videos
10:03Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
Published on: November 18, 2022
08:32Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
Published on: January 4, 2018
Related Concept Videos
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
Intrauterine Drug Delivery Systems
Modified-Release Drug Delivery Systems: Rate-Programmed I